|
| Exchange Disseminated Time | Brooks Laboratories Ltd has informed BSE that the Company has received approval for manufacture of Doripenem Monohydrate Injection from Directorate General of Health Service. The Company is all set to manufacture this drug within this fiscal year.
Doripenem is a broad spectrum anti-bacterial agent of carbapenem family. Growing bacterial resistance is major cause of concern for researchers as it contributors to increase in mortality, morbidity and treatment cost. Doripenem is an ultra broad spectrum anti bacterial agent of carbepenem family used to treat in complicated intra-abdominal infections and complicated urinary tract infections, including complicated and uncomplicated pylenephritis and cases with concurrent bacteremia. |
|
|